Clinical Collaborations

Advances in genetic analysis are revolutionizing the practice of medicine, improving patient care, enabling early disease detection, and advancing the treatment of diseases. Novel assays, based on state of the art gene expression analyses, are being developed to improve disease detection and diagnosis across therapeutic areas. DermTech’s proprietary technology enables a variety of tests including gene expression, DNA mutation and microbiome analyses. This paradigm shifting platform uses stratum corneum tissue collected non-invasively with our Adhesive Skin Collection Kit.

DermTech’s validated platform technology is being used to support drug discovery and development programs focused on cancers and inflammatory diseases in clinical research trials from Phase 1-3. Using DermTech’s proprietary technology, pharma partners can stratify and select patients based on initial skin gene expression profiles, identify biomarkers of specific diseases and disease subsets, and track and predict drug responses.

Current indications include:

  • Alopecia Areata
  • Atopic Dermatitis
  • B-Cell Lymphoma
  • Cosmeceuticals
  • Companion and Complimentary Dx
  • Ewing Sarcoma
  • Follicular Lymphoma
  • GVHD
  • Hidradenitis Suppurativa
  • Lupus
  • Mantle Cell Lymphoma
  • Microbiome
  • Pemphigus
  • Psoriasis
  • T-cell Lymphoma
  • Vitiligo

Growing List of Indications

Contact us to explore how DermTech’s patented platform technology can advance your research and clinical trials.


12 + 2 =